OSAM
SPRY icon

O'Shaughnessy Asset Management’s ARS Pharmaceuticals SPRY Stock Holding History

O'Shaughnessy Asset Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,082
Closed -$33K – 2846
2021
Q2 		$33K Buy
+1,082
New +$34.7K ﹤0.01% 1702

Other funds holding SPRY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

O'Shaughnessy Asset Management's SPRY Position: Q3 2021 in Review

O'Shaughnessy Asset Management sold out of ARS Pharmaceuticals (SPRY) in Q3 2021, closing a stake of 1,082 shares — an estimated $33K sold.

O'Shaughnessy Asset Management first reported a position in SPRY in Q2 2021 and held it in 1 quarter. The position peaked at $33K in Q2 2021. 74 funds tracked by Wall St. Rank hold SPRY as of Q3 2021.

  • O'Shaughnessy Asset Management reported no remaining ARS Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • O'Shaughnessy Asset Management sold 1,082 ARS Pharmaceuticals shares in Q3 2021, an estimated $33K.
  • O'Shaughnessy Asset Management first reported a position in ARS Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • O'Shaughnessy Asset Management's ARS Pharmaceuticals position peaked at $33K in Q2 2021.
  • 74 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2021.

Based on O'Shaughnessy Asset Management's 13F filing for Q3 2021, filed 10 Nov 2021.